Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Werewolf Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 42
- −3 vs. Q2 2021
- Shares held
- 19.0M
- −750.3K (−3.8%) vs. Q2 2021
- Total value
- $326.2M
- −$18.1M (−5.3%) vs. Q2 2021
- New holders
- 2
- 15 more added
- Sold out
- 5
- 12 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HOWL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $3.91M |
| Q1 2026 | 48 | $11.7M |
| Q4 2025 | 51 | $9.34M |
| Q3 2025 | 62 | $41.6M |
| Q2 2025 | 65 | $24.3M |
| Q1 2025 | 70 | $26.7M |
| Q4 2024 | 73 | $41.7M |
| Q3 2024 | 69 | $68.3M |
| Q2 2024 | 71 | $79.3M |
| Q1 2024 | 61 | $209.7M |
| Q4 2023 | 41 | $106.8M |
| Q3 2023 | 35 | $51.1M |
| Q2 2023 | 36 | $73.3M |
| Q1 2023 | 38 | $62.5M |
| Q4 2022 | 39 | $42.8M |
| Q3 2022 | 44 | $94.5M |
| Q2 2022 | 46 | $78.0M |
| Q1 2022 | 49 | $84.3M |
| Q4 2021 | 51 | $228.4M |
| Q3 2021 | 42 | $326.2M |
| Q2 2021 | 45 | $344.3M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Werewolf Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 4,291,881 | $73.6M | 1.02% | 00.0% | Unchanged |
| MPM Asset Management LLC | 4,284,172 | $73.5M | 17.04% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 2,388,011 | $41.0M | 6.36% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 1,752,787 | $30.1M | 0.59% | −800,000−31.3% | Reduced |
| Adage Capital Partners GP, L.L.C. | 985,448 | $16.9M | 0.03% | −15,149−1.5% | Reduced |
| Sphera Funds Management Ltd. | 688,475 | $11.8M | 1.17% | −17,819−2.5% | Reduced |
| Avidity Partners Management LP | 625,120 | $10.7M | 0.27% | −25,145−3.9% | Reduced |
| DC Funds, LP | 589,102 | $10.1M | 39.69% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 563,396 | $9.67M | 1.51% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 400,000 | $6.86M | 0.22% | 00.0% | Unchanged |
| BlackRock Inc. | 369,961 | $6.35M | 0.00% | +4,098+1.1% | Added |
| Nicholas Investment Partners, LP | 296,283 | $5.08M | 0.37% | +1,629+0.6% | Added |
| FMR LLC | 238,500 | $4.09M | 0.00% | −76,500−24.3% | Reduced |
| Platinum Investment Management Ltd | 213,381 | $3.66M | 0.10% | +6,466+3.1% | Added |
| Alyeska Investment Group, L.P. | 206,201 | $3.54M | 0.04% | 00.0% | Unchanged |
| Migdal Insurance & Financial Holdings Ltd. | 187,500 | $3.22M | 0.03% | 00.0% | Unchanged |
| Vanguard Group Inc | 170,265 | $2.92M | 0.00% | −2,862−1.7% | Reduced |
| Caas Capital Management LP | 162,599 | $2.79M | 0.21% | +62,599+62.6% | Added |
| Geode Capital Management, LLC | 136,472 | $2.34M | 0.00% | +28,294+26.2% | Added |
| Russell Investments Group, Ltd. | 125,873 | $2.16M | 0.00% | +125,873 | New |
| State Street Corp | 116,064 | $1.99M | 0.00% | +37,827+48.3% | Added |
| Northern Trust Corp | 70,404 | $1.21M | 0.00% | −5,370−7.1% | Reduced |
| Bank of New York Mellon Corp | 29,789 | $512.0K | 0.00% | +7,576+34.1% | Added |
| Nuveen Asset Management, LLC | 19,963 | $396.0K | 0.00% | +7,962+66.3% | Added |
| Evercore Wealth Management, LLC | 21,500 | $369.0K | 0.01% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 19,422 | $334.0K | 0.00% | +3,384+21.1% | Added |
| Levin Capital Strategies, L.P. | 15,000 | $257.0K | 0.03% | +15,000 | New |
| New York State Common Retirement Fund | 14,765 | $253.0K | 0.00% | +1,734+13.3% | Added |
| Deutsche Bank AG | 4,351 | $75.0K | 0.00% | −141−3.1% | Reduced |
| American International Group, Inc. | 4,143 | $71.0K | 0.00% | −98−2.3% | Reduced |
| California State Teachers Retirement System | 4,042 | $69.0K | 0.00% | −6,423−61.4% | Reduced |
| JPMorgan Chase & Co | 3,848 | $66.0K | 0.00% | −5,504−58.9% | Reduced |
| STRS Ohio | 1,800 | $30.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,639 | $28.0K | 0.00% | +639+63.9% | Added |
| Morgan Stanley | 1,514 | $26.0K | 0.00% | +1,247+467.0% | Added |
| Citigroup Inc | 867 | $15.0K | 0.00% | −1,149−57.0% | Reduced |
| Royal Bank of Canada | 796 | $14.0K | 0.00% | +277+53.4% | Added |
| Legal & General Group Plc | 736 | $13.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 619 | $11.0K | 0.00% | +132+27.1% | Added |
| Ameritas Investment Partners, Inc. | 593 | $10.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 418 | $7.00K | 0.00% | +366+703.8% | Added |
| Financial Perspectives, Inc | 250 | $4.29K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −37,435−100.0% | Sold out |
| Aristides Capital LLC | 0 | $0 | 0.00% | −25,585−100.0% | Sold out |
| Arena Capital Advisors, LLC- CA | 0 | $0 | 0.00% | −14,958−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −11,300−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |